Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 98,888 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 98,888 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $5.01, for a total value of $495,428.88. Following the completion of the transaction, the chief executive officer now directly owns 15,078,624 shares of the company’s stock, valued at $75,543,906.24. This represents a 0.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $16,000.00.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Performance

Shares of NASDAQ VRNA opened at $39.11 on Tuesday. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $40.76. The company has a market cap of $3.13 billion, a PE ratio of -20.37 and a beta of 0.46. The stock has a 50 day simple moving average of $34.85 and a 200-day simple moving average of $25.61. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93.

Verona Pharma (NASDAQ:VRNA) last announced its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to analysts’ expectations of $2.31 million. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. On average, equities research analysts forecast that Verona Pharma plc will post -2.11 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. HC Wainwright upped their target price on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Truist Financial increased their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company boosted their price objective on Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $43.83.

Institutional Investors Weigh In On Verona Pharma

Institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after buying an additional 529 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Verona Pharma by 70.6% in the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after acquiring an additional 553 shares in the last quarter. CWM LLC bought a new stake in Verona Pharma during the second quarter worth approximately $29,000. EMC Capital Management bought a new stake in Verona Pharma during the second quarter worth approximately $38,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Verona Pharma by 37.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,041 shares of the company’s stock worth $605,000 after purchasing an additional 5,691 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.